{"id":391613,"date":"2014-06-30T00:00:00","date_gmt":"2014-06-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrid0214-biopharma-hospital-discharge-and-outpatient-parenteral-antibiotic-therapy-treatmenttrends-us-2014\/"},"modified":"2026-03-31T09:05:03","modified_gmt":"2026-03-31T09:05:03","slug":"trtrid0214-biopharma-hospital-discharge-and-outpatient-parenteral-antibiotic-therapy-treatmenttrends-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrid0214-biopharma-hospital-discharge-and-outpatient-parenteral-antibiotic-therapy-treatmenttrends-us-2014\/","title":{"rendered":"Hospital Discharge and Outpatient Parenteral Antibiotic Therapy | TreatmentTrends | US | 2014"},"content":{"rendered":"<p>Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs, improve conven-ience for patients and decrease the risk of complications due to hospitalization. Patients with infections requiring often prolonged treatment with intravenous antibiotics and having a relatively low risk of developing fulmi-nant disease are the best candidates for receiving OPAT.<br \/>\nThis report provides insight into the management of hospitalized antibiotic-treated patients after discharge and in the outpatient setting, with an emphasis on OPAT treatment. Through market research with infectious diseases specialists, the report analyzes the post-hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important pathogens, including MRSA, and identifies factors that drive and constrain physician prescribing of key OPAT therapies. The report will also explore the impact of the emerging long-acting glycolipopeptides on OPAT treatment and hospitalization decisions.<\/p>\n","protected":false},"template":"","class_list":["post-391613","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-infectious-disease","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391613\/revisions"}],"predecessor-version":[{"id":394736,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391613\/revisions\/394736"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}